52 active
/
89 total (since 2015)
23
Phase 1 Active
50 total
36
Phase 2 Active
56 total
4
Phase 3 Active
6 total
1
Phase 4 Active
1 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
TuHURA Biosciences, Inc. 2 1 0
ImmunityBio, Inc. 1 0 3
Neonc Technologies, Inc. 1 0 0
Replimune Inc. 1 0 0
Phio Pharmaceuticals Inc. 1 0 0
SystImmune Inc. 1 0 0
AstraZeneca 1 0 0
Sotio Biotech Inc. 1 0 0
GI Innovation, Inc. 1 0 0
Fujifilm Pharmaceuticals U.S.A., Inc. 1 0 0
Memgen, Inc. 1 0 0
Sensei Biotherapeutics, Inc. 1 0 0
Medicenna Therapeutics, Inc. 1 0 0
KaliVir Immunotherapeutics 1 0 0
Checkpoint Therapeutics, Inc. 1 0 0
NCT03712605 ACTIVE NOT RECRUITING
Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial
National Cancer Institute (NCI) n=280
NCT06947928 RECRUITING
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc. n=118
NCT03271372 ACTIVE NOT RECRUITING
Adjuvant Avelumab in Merkel Cell Cancer
University of Washington n=101
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03783078 COMPLETED
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Merck Sharp & Dohme LLC n=55
NCT05896839 RECRUITING
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
NCT05947500 ACTIVE NOT RECRUITING
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
NCT02978625 ACTIVE NOT RECRUITING
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
NCT06047379 RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT04349436 RECRUITING
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Replimune Inc.
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT05496036 RECRUITING
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Abramson Cancer Center at Penn Medicine
NCT06151236 RECRUITING
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Melanoma Institute Australia
NCT07115043 RECRUITING
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07387198 NOT YET RECRUITING
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT06056895 ACTIVE NOT RECRUITING
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
University of Washington
NCT05594290 ACTIVE NOT RECRUITING
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
Gruppo Oncologico del Nord-Ovest
NCT03228667 ACTIVE NOT RECRUITING
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
NCT05100095 RECRUITING
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
M.D. Anderson Cancer Center
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT03071406 ACTIVE NOT RECRUITING
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05120271 ACTIVE NOT RECRUITING
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Sotio Biotech Inc.
NCT02479698 RECRUITING
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT03304639 ACTIVE NOT RECRUITING
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
NCT04869137 ACTIVE NOT RECRUITING
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06814496 RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT03074513 ACTIVE NOT RECRUITING
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
NCT04977453 RECRUITING
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
GI Innovation, Inc.
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT04792073 ACTIVE NOT RECRUITING
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT03935893 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT05583708 RECRUITING
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Weill Medical College of Cornell University
NCT04291885 ACTIVE NOT RECRUITING
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Melanoma and Skin Cancer Trials Limited
NCT06223659 RECRUITING
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ohio State University Comprehensive Cancer Center
NCT04261855 RECRUITING
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
Melanoma and Skin Cancer Trials Limited
NCT05013099 ACTIVE NOT RECRUITING
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb, Inc.
NCT05269381 RECRUITING
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT06086288 NOT YET RECRUITING
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT06939036 TERMINATED
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Ariceum Therapeutics GmbH
NCT04260802 TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
NCT04916002 TERMINATED
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
NCT04725331 TERMINATED
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
NCT03599713 COMPLETED
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
NCT04902040 TERMINATED
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT03167164 WITHDRAWN
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
NCT02819843 COMPLETED
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT03853317 TERMINATED
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
NCT04393753 COMPLETED
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
4SC AG
NCT02465957 TERMINATED
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
ImmunityBio, Inc.
NCT04590781 TERMINATED
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Xencor, Inc.
NCT03435640 TERMINATED
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Nektar Therapeutics
NCT02643303 COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT03684785 TERMINATED
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
NCT02584829 TERMINATED
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
NCT04874831 WITHDRAWN
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
4SC AG
NCT03988647 TERMINATED
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Stanford University
NCT02514824 COMPLETED
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
NCT06014086 ACTIVE NOT RECRUITING
Intratumoral PH-762 for Cutaneous Carcinoma
Phio Pharmaceuticals Inc.
NCT07080242 RECRUITING
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
SystImmune Inc.
NCT04616248 ACTIVE NOT RECRUITING
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT06021626 RECRUITING
A Study of CRD3874-SI in People With Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04975152 ACTIVE NOT RECRUITING
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05859074 RECRUITING
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT06940440 RECRUITING
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
TuHURA Biosciences, Inc.
NCT03816332 ACTIVE NOT RECRUITING
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
NCT04047251 ACTIVE NOT RECRUITING
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT05076760 RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT04272034 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT04116320 TERMINATED
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
Craig L Slingluff, Jr
NCT04242199 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT04160065 COMPLETED
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
TuHURA Biosciences, Inc.
NCT03629756 COMPLETED
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT03798639 COMPLETED
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Claire Verschraegen
NCT05422781 COMPLETED
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
Immunomic Therapeutics, Inc.
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT04596033 TERMINATED
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
NCT03652077 COMPLETED
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03538028 COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Biosciences International Sàrl
NCT02831179 WITHDRAWN
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
NCT05966064 RECRUITING
DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)
Natasha Appelman-Dijkstra
Data: ClinicalTrials.gov